AI주식인사이트AI Stock Insight
B

츌립앤사이언스

291650KOSDAQ

64.3 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40
News Sentiment21.3 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 70.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

AptaMera Science is a biotech company spun off from POSTECH in 2011, specializing in the development of innovative therapeutics based on aptamer technology and offering CRO services for biopharmaceutical analysis. Utilizing its proprietary ApDC® platform, the company is advancing the development of targeted anti-cancer drugs for solid and hematologic malignancies, with key candidates like AST-201 and AST-202 in clinical trials, and expanded into CRO services in 2024.

Number of Employees

44people

Average Salary

54.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.75Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-32.13Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
3.91Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲284.5% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲15.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -45.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position6.0Point

52w upper range (71%)

Current 1,616Won52-week high 1,99052-week low 684
1-month return6.0Point

1m +70.11% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-08-20
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-20
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-20
  • Neutral주식등의대량보유상황보고서(약식)2026-08-20
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-20